R & D Days

Five Prime R & D Day December 2016

Five Prime R & D Day May 2015


Cabiralizumab (FPA008, CSF1R inhibitor antibody)

American Society of Clinical Oncology (ASCO), June 2018

Carleton M, et al.

ABSTRACT: Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications​

The Journal of Rheumatology, October 2017

JOURNAL: Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark
Ehrenstein, V, Andersen, S, et al.
The Journal of Rheumatology 44  (10)  1476-1483
DOI: 10.3899/jrheum.160816

2017 SITC Late-Breaker Oral Presentation, November 2017

Wainberg Z, et al.

ORAL PRESENTATION: First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (cabiralizumab) Plus Anti–PD-1 (nivolumab), in Patients With Advanced Solid Tumors

2017 American Society of Clinical Oncology (ASCO), June 2017

K. Kumar Sankhala et al.

POSTER: A Phase 1/2 Dose Escalation and Expansion Study of Cabiralizumab (FPA008), an anti-CSF1R antibody, in Tenosynovial Giant Cell Tumor (TGCT, Diffuse Pigmented Villonodular Synovitis D-PVNS)

2017 American Society of Clinical Oncology (ASCO), June 2017

Kamalesh S, et al.

ABSTRACT: Cabiralizumab PVNS ASCO 2017 Final Abstract

American Association for Cancer Research (AACR), April 2017

Bellovin D, et al.

POSTER: Antibody-Based Inhibition of CSF-1R as a Component of Combination Immunotherapy in Preclinical Models

American College of Rheumatology (ACR), November 2015

Zhou L, Sikorski R, et al.

POSTER: A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients with Rheumatoid Arthritis (RA): Preliminary Results

ABSTRACT: A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Subjects with Rheumatoid Arthritis (RA): Preliminary Results

Society for Immunotherapy of Cancer (SITC), November 2015

Bellovin D, Wondyfraw N, et al.

POSTER: cmFPA008, an Anti-Mouse CSF-1R Antibody, Combines with Multiple Immunotherapies to Reduce Tumor Growth in Nonclinical Models Poster

ABSTRACT: cmFPA008, an Anti-Mouse CSF-1R Antibody, Combines with Multiple Immunotherapies to Reduce Tumor Growth in Nonclinical Models

CRI-CIMT-EATI-AACR, September 2015

Brahmer J, Rasco D, et al.

POSTER: A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers Poster

ABSTRACT: A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers

American College of Rheumatology (ACR), November 2014

POSTER: A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results

Journal of Leukocyte Biology, September 2010

JOURNAL: Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells
Wei S, Nandi S, Chitu V, et al.
J Leukoc Biol
2010;88:495–505.

Science, May 2008

JOURNAL: Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome
Lin H, Lee E, et al.
Science 9 May 2008: 807-811
DOI: 10.1126/science.1154370


FPA144 (anti-FGF receptor 2b antibody)

American Society of Clinical Oncology (ASCO), June 2018

Catenacci D, et al.

ABSTRACT: FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in​

2017 Society for Immunotherapy of Cancer (SITC), November 2017

Lee Y, et al.

POSTER: FGFR2b expression and baseline immune signature to guide FPA144 development in urothelial cancer

2017 American Society of Clinical Oncology (ASCO), June 2017

Catenacci, et al.

POSTER: Updated Antitumor Activity and Safety of FPA144, an ADCC-enhanced, FGFR2b Isoform-specific Monoclonal Antibody, in Patients with FGFR2b+ Gastric Cancer

2017 American Society of Clinical Oncology (ASCO), June 2017

Catenacci D, et al.

ABSTRACT: FPA144 ASCO 2017 Final Abstract

EORTC-NCI-AACR, December 2016

Ghoddusi M, Pierce K, et al.

POSTER: FGFR2b Represents a Novel Target for Treatment of Urothelial Cancer

American Society of Clinical Oncology (ASCO), June 2016

Lee J, Bendell J, et al.

PRESENTATION: Antitumor Activity and Safety of FPA144, an ADCC enhanced, FGFR2b Isoform-Selective Monoclonal Antibody, in Patients with FGFR2b+ Gastric Cancer and Advanced Solid Tumors

American Association for Cancer Research (AACR), April 2016

Pierce, K.

PRESENTATION: FPA144: A Therapeutic Monoclonal Antibody with Enhanced Antibody-Dependent Cell Killing for the Treatment of Fibroblast Growth Factor Receptor 2b Overexpressing Cancers

Powers J, Palencia S, et al.

POSTER: FPA144, a Therapeutic Monoclonal Antibody Targeting the FGFR2b Receptor, Promotes Antibody Dependent Cell-Mediated Cytotoxicity and Stimulates Sensitivity to PD-1 Blockade in the 4T1 Syngeneic Tumor Model in Mice

ABSTRACT: FPA144, a Therapeutic Monoclonal Antibody Targeting the FGFR2b Receptor, Promotes Antibody Dependent Cell-Mediated Cytotoxicity and Stimulates Sensitivity to PD-1 the 4T1 Breast Tumor Model in Mice

ASCO Gastrointestinal Cancers Symposium, January 2016

Bendell J, Rogers S, et al.

POSTER: FPA144-001: A First in Human Study of FPA144, an ADCC-enhanced, FGFR2b Isoform-selective Monoclonal Antibody in Patients with Advanced Solid Tumors

American Association for Cancer Research (AACR), April 2014

Gemo A, Deshpande A, et al.

POSTER: FPA144: A Therapeutic Antibody for Treating Patients with Gastric Cancers Bearing FGFR2 Gene Amplification


FP-1039 (FGF ligand trap)

European Society for Medical Oncology (ESMO) 2017 Congress, September 2017

Trigo, Jose et al.

ABSTRACT: Multicenter, Nonrandomized, Open-Label Phase 1b Study of FP-1039/GSK3052230 with Chemotherapy: Results in Malignant Pleural Mesothelioma (MPM)

POSTER: Multicenter, Nonrandomized, Open-Label Phase 1b Study of FP-1039/GSK3052230 with Chemotherapy: Results in Malignant Pleural Mesothelioma (MPM)

American Society of Clinical Oncology (ASCO), June 2016

Trigo J, van Brummelen E, et al.

POSTER: Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) with deregulated fibroblast growth factor (FGF) pathway signaling: interim results in MPM

Annals of Oncology, December 2015

JOURNAL: A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors
Tolcher A, Papadopoulos K, et al.
Annals of Oncology 27: 526–532, 2016
doi:10.1093/annonc/mdv591 

World Conference on Lung Cancer, September 2015

Garrido P, Delgado I, et al.

ABSTRACT: FP1039/GSK3052230 with chemotherapy in patients with fibroblast growth factor (FGF) pathway deregulated squamous NSCLC or MPM

PRESENTATION: FP1039/GSK3052230 with chemotherapy in patients with fibroblast growth factor (FGF) pathway deregulated squamous NSCLC or MPM

American Association for Cancer Research (AACR), April 2014

DeYoung M, Sherk C, et al.

POSTER: Preclinical efficacy of targeting FGF autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230

Bellovin D, Palencia S, et al.

POSTER: FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC

Science Translational Medicine, March 2013

JOURNAL: Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer

Supplemental Materials
Harding, et al.
Sci Transl Med 27 March 2013:
Vol. 5, Issue 178, p. 178ra39

American Association for Cancer Research (AACR), April 2012

Harding T, Palencia S, et al.

POSTER: Preclinical efficacy of fibroblast growth factor ligand trap HGS1036 in lung carcinoma models with genomic amplification of FGFR1

EORTC-NCI-AACR, November 2010

Tolcher A, Papadopoulos K, et al.

POSTER: Preliminary Results of a Dose Escalation Study of the Fibroblast Growth Factor (FGF) “trap” FP-1039 (FGFR1:Fc) In Patients With Advanced Malignancies

American Society of Clinical Oncology (ASCO), June 2010

Keer H, Harding T, et al.

POSTER: Enrolling a Rare Patient Population: Establishing Proof of Concept for FP-1039,an FGF “Trap,” in Endometrial Cancer Patients with the S252W FGFR2 Mutation

American Association for Cancer Research (AACR), April 2010

Harding T, Palencia S, et al.

POSTER: Preclinical Effi cacy of FP-1039 (FGFR1:Fc) in Endometrial Carcinoma Models with Activating Mutations in FGFR2

AACR-EORTC-NCI, November 2009

Tolcher A, Papadopoulos K, et al.

POSTER: Preliminary Results of a Phase 1 Study of FP-1039 (FGFR1:Fc), A Novel Antagonist Of Multiple Fibroblast Growth Factor (FGF) Ligands, In Patients With Advanced Malignancies

American Association for Cancer Research (AACR), April 2009

Long L, Brennan T, et al.

POSTER: Preclinical Antitumor Efficacy of FP-1039, A Soluble FGF Receptor 1:Fc Conjugate, as a Single Agent or in Combination with Anticancer Drugs

AACR-NCI-EORTC, October 2007

Zhang H, Masuoka L, et al.

POSTER: FP-1039 (FGFR1:Fc), A Soluble FGFR1 Receptor Antagonist, Inhibits Tumor Growth and Angiogenesis


FPA150 (B7-H4 antibody)

American Association for Cancer Research (AACR), April 2018

Kaplan, Charles et al.

PRESENTATION:  FPA150: A First-In-Class T Cell Checkpoint Blocking Antibody with ADCC Activity for the Treatment of Malignancies that Express High Levels of B7-H4

European Society for Medical Oncology (ESMO) 2017 Congress, September 2017

Kaplan, Charles et al.

ABSTRACT:  FPA150, a Novel B7-H4 Therapeutic Antibody with Checkpoint Blockade and ADCC Activities

POSTER: FPA150, a Novel B7-H4 Therapeutic Antibody with Checkpoint Blockade and ADCC Activities


FPA154 (GITR agonist antibody)

American Association for Cancer Research (AACR), April 2017

Barbee S, et al.

POSTER: Development of FPA154, a novel tetravalent anti-GITR antibody, for the treatment of solid tumors

Society for Immunotherapy of Cancer (SITC), November 2016

Barbee S, Bellovin D, et al.

POSTER: Novel tetravalent anti-GITR antibody is a potent anti-tumor agent in vivo


FPT155 (CD80-Fc)

American Association for Cancer Research (AACR), October 2017

Barbee S, et al.

POSTER: FPT155, A Novel Therapeutic CD80-Fc Fusion Protein With Potent Antitumor Activity in Preclinical Models


Discovery Platform, Immuno-Oncology Research, and Respiratory Research

American Association for Cancer Research (AACR), April 2017

Brace A, et al.

POSTER: Identification Of Novel T Cell Co-inhibitory And Co-stimulatory Receptors From Screening A Comprehensive Library Of Extracellular Proteins

American Thoracic Society (ATS), May 2015

Zhu Y, Gosling J, et al.

POSTER: A High Content Screen to Identify Novel Factors That Restore Phagocytosis in COPD Alveolar Macrophages

Keystone Symposium, 2015

Sullivan K, Huang K, et al.

POSTER: An in vitro Co-culture Model to Characterize Cross-talk between COPD Airway Epithelia and Dendritic Cells

Society for Immunotherapy of Cancer (SITC), November 2014

Sallee N, Lee E, et al.

POSTER: Discovery of Novel Immune Checkpoint Regulators in a Comprehensive Library of Human Extracellular Proteins

Proceedings of the National Academy of Sciences (PNAS), September 2014

JOURNAL: Deorphanization of the human leukocyte tyrosinekinase (LTK) receptor by a signaling screen of the extracellular proteome
Zhang H, Pao L, et al.
www.pnas.org/cgi/doi/10.1073/pnas.1412009111

Combinatorial Chemistry & High Throughput Screening, February 2009

JOURNAL: Controlling Feature Selection in Random Forests of Decision Trees Using a Genetic Algorithm: Classification of Class I MHC Peptides.
Hansen L, Lee E, et al.
Combinatorial Chemistry & High Throughput Screening, 2009
Vol. 12, No. 5, 514-519

Drug Discovery Today, August 2006

JOURNAL: HTS Technologies in Biopharmaceutical Discovery
Ge Wu, Stephen K. Doberstein
Volume 11, Issues 15–16, August 2006, Pages 718–724
Drug Discovery Today, 11:15-16.


IO Research and Preclinical

Society for Immunotherapy of Cancer (SITC), November 2015

Sallee N, Karasyov A, et al.

POSTER: Identification of a Novel T Cell Co-Inhibitory Receptor and Potential Therapeutic Antibody Target in Oncology Poster

ABSTRACT: Identification of a Novel T Cell Co-Inhibitory Receptor and Potential Therapeutic Antibody Target in Oncology

Brennan T, Bellovin D, et al.

POSTER: Identification of Novel Immune Regulators of Tumor Growth Using RIPPS Screening in vivo Poster

ABSTRACT: Identification of Novel Immune Regulators of Tumor Growth Using RIPPS Screening in vivo